TP53, tumor protein p53, 7157

N. diseases: 2494; N. variants: 527
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.700 GeneticVariation group CLINVAR
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.700 AlteredExpression group BEFREE We have found that the expression of p53 messenger RNA is growth regulated in human cells following kinetics similar to that previously shown in mouse 3T3 cells, and is increased in the large majority of colon adenocarcinomas in comparison to adjacent normal mucosa and adenoma. 3019534 1986
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.700 Biomarker group BEFREE Simultaneous monitoring of P53 protein and DNA content of colorectal adenocarcinomas by flow cytometry. 2137812 1990
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.700 GeneticVariation group BEFREE We analyzed 15 aneuploid populations and one tetraploid populations from 13 Barrett's adenocarcinomas for 17p allelic deletions and p53 protein overexpression to determine whether both of these alterations are involved in carcinogenesis in Barrett's esophagus. 1680552 1991
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.700 Biomarker group BEFREE Mucinous carcinomas and right-side carcinomas were less p53 immunoreactive (25% and 52%, respectively) than the usual adenocarcinomas (73%) and distal tumors (72%). 1868464 1991
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.700 Biomarker group BEFREE Although the number of p53 negative adenocarcinomas without metastasis was larger than the number of p53 positive tumors without metastasis, there were not clear differences between p53 positive and negative tumors with metastasis. 1656762 1991
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.700 Biomarker group BEFREE However, the finding of p53 mutations in Barrett's epithelium adjacent to adenocarcinomas may have clinical implications for p53 as a premalignant marker for esophageal cancer. 1943188 1991
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.700 AlteredExpression group BEFREE Our study indicates that there might be an association between accumulation of p53 protein and c-myc over-expression in non-small-cell lung cancer, and that this in particular might apply to adenocarcinomas. 1334053 1992
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.700 AlteredExpression group BEFREE In this series of ovarian tumours, LOH on 17p correlates closely with the aberrant expression of the p53 protein in a high proportion of advanced stage serous adenocarcinomas. 1310251 1992
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.700 GeneticVariation group BEFREE Among four adenocarcinomas arising in the lowest portion of the uterine corpus, three showed integration of human papillomavirus (HPV) types 16 and/or 18 DNA, and two of them also showed p53 mutation. 1336492 1992
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.700 Biomarker group BEFREE Immunohistochemical staining for the p53 protein was performed in 107 snap frozen primary endometrial adenocarcinomas and 15 benign uterine tissues using monoclonal antibody PAb1801. 1540970 1992
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.700 Biomarker group BEFREE These genes include 1) those important to androgen metabolism in the prostate, the androgen receptor and steroid 5 alpha reductase genes; 2) those that map to the 10q (PLAU) and 7q (MET) chromosomal regions found deleted in some prostate carcinomas, and 3) proto-oncogenes (ERBB2, INT2, and MYC) and tumor suppressor gene loci (RB1, TP53 and D17S5) found altered in adenocarcinomas of the breast, colon and lung. 1552612 1992
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.700 AlteredExpression group BEFREE In this study we investigated immunohistochemically the expression of p53 and c-erbB-2 proteins in 30 gall bladder adenocarcinomas, one carcinoma in situ, eight gall bladder epithelial dysplasias, and four cases of chronic cholecystitis. p53 expression could be found in 14 (47 per cent) adenocarcinomas and in two out of eight epithelial dysplasias. 8100854 1993
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.700 Biomarker group BEFREE Mutant P53 protein was present in 58.6 percent of anal cancers overall and in 85.7 percent of anal adenocarcinomas. 8223054 1993
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.700 GeneticVariation group BEFREE To reveal the role of the p53 tumor suppressor gene in the development of endometrial adenocarcinoma and to study the association of p53 alterations with K-ras activation, an additional 28 endometrial adenocarcinomas and an additional 11 premalignant atypical uterine hyperplasias (series 3), as well as 12 cases of endometrial adenocarcinoma (10 having K- or N-ras activation) and 2 cases of atypical hyperplasia from series 1 and 2, were screened for the presence of p53 alterations. 8385572 1993
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.700 Biomarker group BEFREE Immunohistochemistry with PAb 1801 monoclonal antibody was performed on archival material; p53 nuclear staining was seen in 10/17 adenomas, but was limited to the foci of adenocarcinoma in three cases. 8237942 1993
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.700 Biomarker group BEFREE DNA sequence and single strand conformational polymorphism analyses were used to evaluate p53 in 27 squamous carcinomas (25 HPV-positive) and eight adenocarcinomas (four HPV-positive). 8238255 1993
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.700 GeneticVariation group BEFREE Seven cases showed p53 gene mutations: four advanced-stage adenocarcinomas, the papillary carcinoma, the neuroendocrine carcinoma, and the adenoma with foci of carcinoma. 8475992 1993
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.700 GeneticVariation group BEFREE Pancreatic adenocarcinomas frequently show p53 gene mutations. 8494051 1993
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.700 AlteredExpression group BEFREE Eight of 11 adenocarcinomas overexpressed the p53 protein. 8496390 1993
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.700 Biomarker group BEFREE Conversely, the development of poorly differentiated adenocarcinoma, in addition to changes in p53 and c-met genes, requires reduction or dysfunction of cadherin. 8440743 1993
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.700 AlteredExpression group BEFREE Although p53 was expressed more commonly in adenocarcinoma (30% of 10) and squamous carcinoma (28% of 29) than in small cell tumors (10% of 20), this could be accounted for by the smoking history. 8390213 1993
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.700 AlteredExpression group BEFREE Pancreatic expression of the p53 tumor suppressor gene was studied in pancreatic adenocarcinomas and chronic pancreatitis. 8513440 1993
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.700 GeneticVariation group BEFREE Two adenocarcinomas with allelic loss on 17p contained a mutant p53 gene in the allele that was retained. 8473053 1993
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.700 GeneticVariation group BEFREE Progression to the adenocarcinoma phenotype was shown to involve a specific chromosome 1 rearrangement, loss of both normal copies of chromosome 18 (although DCC gene sequences were retained), loss of the remaining wild type allele of k-ras resulting in homozygosity for the k-ras codon 12 mutation and increased cellular p53 protein as detected by SDS-PAGE Western blotting. 8414507 1993